Modified VRC01 Antibodies Enhance HIV-1 Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current neutralizing antibodies for HIV-1, such as VRC01-class antibodies, have limitations in recognizing and neutralizing varying HIV-1 strains, necessitating the development of additional antibodies with improved binding and neutralization profiles.
Innovation Solution
Modified VRC01-class antibodies with specific substitutions and deletions in their heavy and light chain complementarity determining regions, particularly in the heavy chain variable region framework 3, enhance quaternary interactions with HIV-1 Env trimers, improving binding and neutralization efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If VRC01-class antibodies are used to neutralize HIV-1, then neutralization activity is achieved, but binding affinity and neutralization potency are limited
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence at Kabat positions 72-76 in the HFR3 of VRC01-class antibodies. Specifically, replacing these residues with the sequence QLSQDPDDPDWG (SEQ ID NO: 36) fundamentally alters the antibody's binding parameters, resulting in enhanced binding affinity and neutralization potency while maintaining the original neutralization mechanism.
2Reliability
If VRC01-class antibodies bind to CD4 binding site, then neutralization is achieved, but recognition of varying HIV-1 strains is limited
Solution Approach 1:
The patent modifies the binding parameters of VRC01-class antibodies by introducing specific amino acid substitutions in the HFR3 region. These parameter changes enable the antibodies to maintain their CD4 binding site specificity while expanding their ability to recognize and neutralize a broader range of HIV-1 strains with varying envelope proteins.
Data Source
AI summary
Antibodies and antigen binding fragments that specifically bind to HIV-1 Env and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.